{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:52:53Z","timestamp":1776919973981,"version":"3.51.2"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003646","name":"National Health Insurance Service","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.bone.2020.115650","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T23:14:56Z","timestamp":1600470896000},"page":"115650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Incidence of and risk for osteonecrosis of the jaw in Korean osteoporosis patients treated with bisphosphonates: A nationwide cohort-study"],"prefix":"10.1016","volume":"143","author":[{"given":"Se Hwa","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Kyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Chan","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunmee","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ha Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2020.115650_bb0005","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA."},{"key":"10.1016\/j.bone.2020.115650_bb0010","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA."},{"key":"10.1016\/j.bone.2020.115650_bb0015","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1359\/jbmr.2000.15.4.613","article-title":"Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib","volume":"15","author":"Mashiba","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115650_bb0020","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115650_bb0025","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws","volume":"65","author":"Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws AAoO","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bone.2020.115650_bb0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.bone.2020.115650_bb0035","doi-asserted-by":"crossref","unstructured":"A.A Khan, L.P. Rios, G.K. Sandor, N. Khan, E. Peters, M.O. Rahman, et al. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. J Rheumatol. 38 (2011) 1396\u20131402.","DOI":"10.3899\/jrheum.100221"},{"key":"10.1016\/j.bone.2020.115650_bb0040","first-page":"691","article-title":"Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study","volume":"35","author":"Etminan","year":"2008","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bone.2020.115650_bb0045","doi-asserted-by":"crossref","unstructured":"P. Tennis, K.J. Rothman, R.L Bohn, H. Tan, A. Zavras, C. Laskarides, et al. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf. 21 (2012) 810\u2013817.","DOI":"10.1002\/pds.3292"},{"key":"10.1016\/j.bone.2020.115650_bb0050","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.joms.2013.06.221","article-title":"Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate","volume":"72","author":"Ulmner","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2020.115650_bb0055","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115650_bb0060","doi-asserted-by":"crossref","unstructured":"J.T. Grbic, R. Landesberg, S.Q Lin, P. Mesenbrink, I.R Reid, P.C. Leung, et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc. 139 (2008) 32\u201340.","DOI":"10.14219\/jada.archive.2008.0017"},{"key":"10.1016\/j.bone.2020.115650_bb0065","doi-asserted-by":"crossref","unstructured":"J.P. Devogelaer, J.P Brown, P. Burckhardt, P.J. Meunier, S. Goemaere, K. Lippuner, et al. Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int. 18 (2007) 1211\u20131218.","DOI":"10.1007\/s00198-007-0367-3"},{"key":"10.1016\/j.bone.2020.115650_bb0070","doi-asserted-by":"crossref","unstructured":"P.P. Sedghizadeh, K. Stanley, M. Caligiuri, S. Hofkes, B Lowry, C.F. Shuler. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc. 140 (2009) 61\u201366.","DOI":"10.14219\/jada.archive.2009.0019"},{"key":"10.1016\/j.bone.2020.115650_bb0075","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00198-014-2624-6","article-title":"Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population","volume":"25","author":"Lin","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115650_bb0080","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1210\/jc.2013-4119","article-title":"The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene","volume":"99","author":"Chiu","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115650_bb0085","doi-asserted-by":"crossref","first-page":"212S","DOI":"10.1177\/0022034515587862","article-title":"A large national cohort study of the association between bisphosphonates and osteonecrosis of the jaw in patients with osteoporosis: a nested case-control study","volume":"94","author":"Kwon","year":"2015","journal-title":"J. Dent. Res."},{"key":"10.1016\/j.bone.2020.115650_bb0090","doi-asserted-by":"crossref","unstructured":"J.C. Lo, F.S O'Ryan, N.P. Gordon, J. Yang, R.L. Hui, D. Martin, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 68 (2010) 243\u2013253.","DOI":"10.1016\/j.joms.2009.03.050"},{"key":"10.1016\/j.bone.2020.115650_bb0095","first-page":"299","article-title":"Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR Dental PBRN","volume":"130","author":"Barasch","year":"2013","journal-title":"Tex. Dent. J."},{"key":"10.1016\/j.bone.2020.115650_bb0100","doi-asserted-by":"crossref","unstructured":"F. Lapi, F. Cipriani, A.P Caputi, G. Corrao, A. Vaccheri, M.C. Sturkenboom, et al. Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures. Osteoporos Int.24 (2013) 697\u2013705.","DOI":"10.1007\/s00198-012-2013-y"},{"key":"10.1016\/j.bone.2020.115650_bb0105","doi-asserted-by":"crossref","unstructured":"F. Jadu, L Lee, M. Pharoah, D. Reece, L. Wang. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol. 18 (2007) 2015\u20132019.","DOI":"10.1093\/annonc\/mdm370"},{"key":"10.1016\/j.bone.2020.115650_bb0110","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00774-009-0047-9","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid","volume":"27","author":"Cetiner","year":"2009","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2020.115650_bb0115","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115650_bb0120","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bone.2009.07.011","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation?","volume":"45","author":"Lesclous","year":"2009","journal-title":"Bone."},{"key":"10.1016\/j.bone.2020.115650_bb0125","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/COC.0b013e3182155fcb","article-title":"A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates","volume":"35","author":"Thumbigere-Math","year":"2012","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.bone.2020.115650_bb0130","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw","volume":"27","author":"Vahtsevanos","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bone.2020.115650_bb0135","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2008.16.2768","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients","volume":"26","author":"Kyrgidis","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bone.2020.115650_bb0140","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.joms.2013.02.016","article-title":"Oral health risk factors for bisphosphonate-associated jaw osteonecrosis","volume":"71","author":"Tsao","year":"2013","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2020.115650_bb0145","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3899\/jrheum.120810","article-title":"Osteonecrosis of the jaw and nonmalignant disease: is there an association with rheumatoid arthritis?","volume":"40","author":"Lescaille","year":"2013","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bone.2020.115650_bb0150","doi-asserted-by":"crossref","unstructured":"N. Conte Neto, A.S. Bastos, R.A. Chierici-Marcantonio, E.Jr. Marcantonio. Is rheumatoid arthritis a risk factor for oral bisphosphonate-induced osteonecrosis of the jaws? Med Hypotheses. 77 (2011) 905\u2013911.","DOI":"10.1016\/j.mehy.2011.08.008"},{"key":"10.1016\/j.bone.2020.115650_bb0155","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/jbmr.2827","article-title":"Rheumatoid arthritis exacerbates the severity of osteonecrosis of the jaws (ONJ) in mice: a randomized, prospective, controlled animal study","volume":"31","author":"de Molon","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115650_bb0160","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1210\/jc.2006-2036","article-title":"Possible association between diabetes and bisphosphonate-related jaw osteonecrosis","volume":"92","author":"Khamaisi","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115650_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CLEP.S37664","article-title":"Evaluation of an algorithm ascertaining cases of osteonecrosis of the jaw in the Swedish National Patient Register","volume":"5","author":"Bergdahl","year":"2013","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.bone.2020.115650_bb0170","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00198-009-1024-9","article-title":"Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia","volume":"21","author":"Hong","year":"2010","journal-title":"Osteoporos. Int."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220304300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220304300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:55:03Z","timestamp":1757613303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328220304300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":34,"alternative-id":["S8756328220304300"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115650","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of and risk for osteonecrosis of the jaw in Korean osteoporosis patients treated with bisphosphonates: A nationwide cohort-study","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115650","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115650"}}